Who we are
Women • Health • First
At Nevia, we are focused on women's health.
Our mission is to use innovative technologies to provide early detection of diseases through vaginal secretions analysis, enabled by Nevia's Machine Learning Platform.
We believe in empowering women to take control of their health by providing them with the tools they need to live a healthy life. Our team is made up of passionate individuals with diverse backgrounds in healthcare, technology, and business.
Together, we are working towards a future where women's health is a top priority.
Founders
CEO & Co-founder
Inbal Zafir Lavie, PhD
CSO & Founder
Shlomit Yehudai Reshef, PhD
Co-founder
Roni Michaely, PhD
Team
Scientific Project Manager and
Regulatory Affairs Specialist
Clinial Operations Manager
Shiri Blumenfeld Kan, PhD, MBA
Valeria Miller, BSc, MBA
Data Scientist
Zohar Shnaider
Board of Directors
CEO & Co-founder
Inbal Zafir Lavie, PhD
CSO & Founder
Shlomit Yehudai Reshef, PhD
Chair of the board
Anula Jayasuriya
MD, PhD, MBA
Board member
Ophir Shoham
Board member
Dan Shwarzman
Advisory Board
Prof. Rob Coleman
Chief Medical Officer, Vaniam Group, GOG Partners, Special Advisor to the President, GOG Foundation, Board Of Directors
Prof. Brian Slomovitz
Director, Gynicologic Oncology and CoChair, Cancer Research Committee, Mount Sinai Medical Center, Board of Directors and Uterine Cancer Lead, GOG Foundation
Prof. Eitan Friedman
Director and founder of the The Suzanne Levy-Gertner Oncogenetics Unit at the Sheba Medical Center
Prof. Ruth Perets
Medical Oncologist Rambam Division of Oncology. Head of the Women's Cancers Research Lab at Rambam Health Care Campus. Directs the Phase 1 Clinical Trials in Oncology
Dr. Orna Berry
A computer scientist, high-tech entrepreneur, and senior executive in the Israeli science and technology industries.
Serves as director of technology in the office of the CTO at Google Cloud.
Our
Solution
Simple vaginal swab
Biomarkers data
Ovarian cancer is also called “the silent killer".
More than 310,000 cases are diagnosed every year worldwide, and 75% of patients are diagnosed at late stages, resulting in less than 30% survival rates.
Therefore, there is a growing demand for early-diagnosis solutions.
Nevia's platform will save lives of women around the world by enabling early detection.
Machine learning
Identify patients
Pipeline
Program
Indication
Development Stage
Biobank
Clinical
POC
FDA
Approval
Nevia-001
Nevia-002
Nevia-003
Ovarian cancer
Endometriosis
To be disclosed
Why Us
HLTH Diverse founders
Israeli femtech innovation leadership award
First Place Pitch Competition
Top 20 most promising companies